A Secret Weapon For SGC-CBP30
123). It's notable that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for loss of Gls in MYC-induced mouse liver tumours40. This means that GLS2 could confer resistance to GLS1-particular inhibitors, like the allosteric inhibitor BPTES or CB-839, which resistance might be hypothetically averted by the usage of a twin